Competing interests {28}
AD
AD received consulting fees and is member of the scientific advisory board of Enalare Therapeutics (USA) and member of the scientific board of MyCB1 Group BV (the Netherlands). AD received grants from ZonMW, the Hague (the Netherlands), and an award from the US Food and Drug Administration (USA). All other authors declare that they have no competing interests.